NDAORALTABLET, EXTENDED RELEASE
Approved
Apr 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
KLOR-CON (potassium chloride) by Ascentage Pharma is tissues. First approved in 1986.
Drug data last refreshed 36m ago · AI intelligence enriched 36m ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KLOR-CON is an oral extended-release tablet formulation of potassium chloride, an essential electrolyte used to treat and prevent hypokalemia (low potassium levels). Potassium ions are critical for maintaining cell tonicity, nerve impulse transmission, and cardiac and skeletal muscle contraction. The product replaces deficient potassium in patients unable to maintain adequate levels through diet alone.
$11MPart D
LOE ApproachingDeclining
Declining revenue and imminent loss of exclusivity signal a shrinking brand team with focus on cost containment and generic transition management.
Mechanism of Action
tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KLOR-CON offers limited career growth opportunity given the product's LOE-approaching lifecycle and minimal linked job openings. Roles focus on operational efficiency, generic transition, and cost containment rather than growth-oriented commercial or medical development.
Generic Product Manager
Worked on KLOR-CON at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.